New antivirals for the treatment of chronic hepatitis B

References

• Nelson N, Easterbrook P, McMahon B. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20:607–628.
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk R, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555.
   PubMed Web of Science ®Google Scholar
• GBD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171.
   PubMed Web of Science ®Google Scholar
• Yuen M, Seto W, Chow D, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12:1295–1303.
   PubMed Web of Science ®Google Scholar
• Trepo C, Chan H, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–2063.
   PubMed Web of Science ®Google Scholar
• Terrault N, Bzowej N, Chang K, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
   PubMed Web of Science ®Google Scholar
• Chen G, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int. 2017;37(suppl 1):59–66.
   PubMedGoogle Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Apr 18. pii: S0168-8278(17)30185-X. doi: 10.1016/j.jhep.2017.03.021. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Seto W, Hui A, Wong V, et al. Treatment cessation of entecavir in Asian patients with HBeAg-negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64:667–672.
   PubMed Web of Science ®Google Scholar
• Nassal M. HBV cccDNA: viral persistence reservoir
and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64:1972–1984.
   PubMed Web of Science ®Google Scholar
• Zeisel M, Lucifora J, Mason W, et al. Towards an HBV cure: state-of-the-art and unresolved questions - report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326.
   PubMed Web of Science ®Google Scholar
• Lin C, Kao J. Novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213–222.
   PubMed Web of Science ®Google Scholar
• Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64(suppl 1):S117–31.
   PubMed Web of Science ®Google Scholar
• Liang T, Block T, McMahon B, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015;62:1893–1908.
   PubMed Web of Science ®Google Scholar
• Phyo W. Search for a cure for chronic hepatitis B infection: how close are we? World J Hepatol. 2015;7:1272.
   PubMed Web of Science ®Google Scholar
• Ott J, Stevens G, Groeger J, et al. Global epidemiology of HBV infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219.
   PubMed Web of Science ®Google Scholar
• Ott J, Horn J, Krause G, et al. Time trends of chronic HBV infection over prior decades – a global analysis. J Hepatol. 2017;66:48–54.
   PubMed Web of Science ®Google Scholar
• Revill P, Testoni B, Locarnini S, et al. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016;13:239–248.
   PubMed Web of Science ®Google Scholar
• Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399–1408.
   PubMed Web of Science ®Google Scholar
• Seeger C, Mason W. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672–686.
   PubMed Web of Science ®Google Scholar
• Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5:2243.
   Google Scholar
• Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Curr Opin Virol. 2017;24:38–45.
   PubMedGoogle Scholar
• REVEAL-HBV Study Group, Chen C, Yang H, Iloeje U. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(suppl 5):72–84.
   PubMed Web of Science ®Google Scholar
• Tseng T, Liu C, Yang H, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149.
   PubMed Web of Science ®Google Scholar
• Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic HBV infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015;7:1064–1073.
   PubMedGoogle Scholar
• Voican C, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. 2016;27:2172–2184.
   PubMed Web of Science ®Google Scholar
• Seto W, Chan T, Hwang Y, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology. 2017;65:1451–1461.
   PubMed Web of Science ®Google Scholar
• Pillai A, Anania F, Pearlman B. Reactivation of hepatitis B during hepatitis C treatment with direct-acting antiviral therapy. Am J Gastroenterol. 2016;111:1854–1856.
   PubMed Web of Science ®Google Scholar
• Naggie S. Hepatitis C virus, inflammation, and cellular aging: turning back time. Top Antivir Med. 2017;25:3–6.
   PubMedGoogle Scholar
• Zignego A, Piluso A, Giannini C. HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. Autoimmun Rev. 2008;8:107–111.
   PubMed Web of Science ®Google Scholar
• Lutgehetmann M, Manckle L, Voltz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–694.
   PubMed Web of Science ®Google Scholar
• Sakurai F, Mitani S, Yamamoto T, et al. Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human HBV infection. Sci Rep. 2017;7:45698.
   PubMed Web of Science ®Google Scholar
• Wang L, Cao M, Wei Q, et al. A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice. Plos One. 2017;12:e0175992.
   PubMed Web of Science ®Google Scholar
• Yan Z, Zeng J, Yu Y, et al. HBV circle: A novel tool to investigate hepatitis B virus covalently closed circular DNA. J Hepatol. 2017;66:1149–1157.
   Web of Science ®Google Scholar
• Block T, Rawat S, Brosgart C. Chronic hepatitis B: a wave of new therapies on the horizon. Antivir Res. 2015;121:69–81.
   PubMed Web of Science ®Google Scholar
• Pan J, Tong S, Kang L, et al. New anti-hepatitis B virus drugs under development and evaluation. Curr Opin Infect Dis. 2016;29:632–638.
   PubMed Web of Science ®Google Scholar
• Gish R, Given B, Lai C, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015;121:47–58.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhao Q, Wu S, et al. The current status and future directions of hepatitis B antiviral drug discovery. Exp Op Drug Discover. 2017;12:5–15.
   PubMed Web of Science ®Google Scholar
• Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37(suppl 1):33–39.
   PubMedGoogle Scholar
• Fung J, Lai C, Seto W, et al. Emerging drugs for the treatment of hepatitis B. Expert Opin Emerg Drugs. 2016;21:183–193.
   PubMed Web of Science ®Google Scholar
• Pham E, Perumpail R, Fram B, et al. Future therapy for hepatitis B virus: role of immunomodulators. Curr Hepatol Rep. 2016;15:237–244.
   PubMedGoogle Scholar
• Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–489.
   PubMed Web of Science ®Google Scholar
• Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–498.
   PubMed Web of Science ®Google Scholar
• Soriano V, Sherman K, Barreiro P. Hepatitis delta and HIV infection. Aids. 2017;31:875–884.
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, de Mendoza C, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015;12:344–352.
   PubMed Web of Science ®Google Scholar
• Shirvani-Dastgerdi E, Winer B, Celia-Terrassa A, et al. Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy. J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30198-8. doi: 10.1016/j.jhep.2017.03.027. [Epub ahead of print].
   PubMedGoogle Scholar
• Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–734.
   PubMed Web of Science ®Google Scholar
• Lim Y, Lee Y, Gwak G, et al. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology. 2017 Mar 30. doi: 10.1002/hep.29187. [Epub ahead of print].
   Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689–696.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf N, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Aids. 2012;26:825–831.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.
   PubMed Web of Science ®Google Scholar
• Chan H, Fung S, Seto W, et al. Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B [abstract PS-041]. J Hepatol. 2017;66(suppl 1):S24.
   Web of Science ®Google Scholar
• Lai C, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275–281.
   PubMed Web of Science ®Google Scholar
• Allweiss L, Volz T, Giersch K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162. [Epub ahead of print]
   PubMedGoogle Scholar
• Cole A. Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection. Curr Opin Pharmacol. 2016;30:131–137.
   PubMed Web of Science ®Google Scholar
• Lam A, Shimada T, Dandri M, et al. No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 [abstract FRI-152]. J Hepatol. 2017;66(suppl 1):S477–S478.
   Web of Science ®Google Scholar
• Ding Y, Zhang H, Niu J, et al. Multiple dose study of GLS4JHS, interfering with the assembly of hepatitis B virus core particles, in patients infected with hepatitis B virus [abstract PS-046]. J Hepatol. 2017;66(suppl 1):S27–S28.
   Web of Science ®Google Scholar
• Ward H, Tang L, Poonia B, et al. Treatment of hepatitis B virus: an update. Future Microbiol. 2016;11:1581–1597.
   PubMed Web of Science ®Google Scholar
• Vaillant A. Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antivir Res. 2016;133:32–40.
   PubMed Web of Science ®Google Scholar
• Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naïve Bangladeshi patients with HBeAg+ chronic hepatitis B infection. Plos One. 2016;11:e0156667.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pantea V, Placinta G, et al. Preliminary safety and efficacy of REP-2139 or REP-2165 used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment-naïve Caucasian patients with chronic HBeAg-negative HBV infection. AASLD abstract LB-7. Hepatology. 2016;64(suppl):1122.
   Google Scholar
• Bazinet M, Pantea V, Placinta G, et al. Update on safety and efficacy in the REP 401 protocol: REP 2139-Mgor REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment naïve Caucasian patients with chronic HBeAg negative HBV infection [abstract THU-154]. J Hepatol. 2017;66(suppl 1):S256–S257.
   Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and non-hepatotoxic degradation of nuclear HBV cccDNA. Science. 2014;343:1221–1228.
   PubMed Web of Science ®Google Scholar
• Revill P, Locarnini S. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Curr Opin Pharmacol. 2016;30:144–150.
   PubMed Web of Science ®Google Scholar
• Moyo B, Bloom K, Scott T, et al. Advances with using CRISPR/CAS-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2017 Jan 10. pii: S0168-1702(16)30733-X. doi: 10.1016/j.virusres.2017.01.003. [Epub ahead of print].
   PubMedGoogle Scholar
• Hynes R, Coller B, Porteus M. Toward responsible human genome editing. JAMA. 2017;317:1829–1830.
   PubMed Web of Science ®Google Scholar
• Dong C, Qu L, Wang H, et al. Targeting HBV cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antivir Res. 2015;118:110–117.
   PubMed Web of Science ®Google Scholar
• Kennedy E, Kornepati A, Cullen B. Targeting HBV cccDNA using CRISPR/Cas9. Antivir Res. 2015;123:188–192.
   PubMed Web of Science ®Google Scholar
• Lin G, Zhang K, Li J. Application of CRISPR/Cas9 technology to HBV. Int J Mol Sci. 2015;16:26077–26086.
   PubMed Web of Science ®Google Scholar
• Gish R, Yuen M, Chan H, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antivir Res. 2015;121:97–108.
   PubMed Web of Science ®Google Scholar
• Yuen M, Chan H, Liu S, et al. ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B. Hepatology. 2015;62:1385A.
   Web of Science ®Google Scholar
• Yuen M, Liu K, Chan H, et al. Prolonged RNA interference therapy with ARC-520 injection in treatment naïve, HBeAg-positive and -negative patients with chronic HBV results in significant reductions of HBs antigen [abstract PS-045]. J Hepatol. 2017;66(suppl 1):S24.
   Web of Science ®Google Scholar
• Yang H, Kao J. HBV cure: can we pin our hopes on immunotherapy? Nat Rev Gastroenterol Hepatol. 2015;12:129–131.
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang E, Yang D, et al. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2015;12:273–282.
   PubMed Web of Science ®Google Scholar
• Pauken K, Wherry E. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276.
   PubMed Web of Science ®Google Scholar
• Gane E, Lim Y, Gordon S, et al. The oral toll-like receptor 7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015;63:320–328.
   PubMed Web of Science ®Google Scholar
• Bam R, Hansen D, Irrinki A, et al. TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells. Antimicrob Agents Chemother. 2017;61:e01369–16.
   PubMed Web of Science ®Google Scholar
• Boeijen L, Van Oord G, Hou J, et al. Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620 [abstract FRI-154]. J Hepatol. 2017;66(suppl 1):S478–S479.
   PubMed Web of Science ®Google Scholar
• Rao M, Valentini D, Dodoo E, et al. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017;56:221–228.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky J, Sun L, et al. Genomic and transcriptomic features of response to anti-PD1 therapy in metastatic melanoma. Cell. 2016;165:35–44.
   PubMed Web of Science ®Google Scholar
• Shire N. Cure strategies for hepatitis B virus: the promise of immunotherapy. Clin Pharmacol Drug Dev. 2017;6:186–194.
   PubMed Web of Science ®Google Scholar
• Pei Y, Wang C, Yan S, et al. Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection. J Med Chem. 2017 Apr 21. doi: 10.1021/acs.jmedchem.6b01442. [Epub ahead of print].
   PubMedGoogle Scholar
• Sugarman J, Revill P, Zoulim F, et al. Ethics and hepatitis B cure research. Gut. 2017;66:389–392.
   PubMed Web of Science ®Google Scholar
• Soriano V, Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev. 2015;17:121–122.
   PubMed Web of Science ®Google Scholar
• Hong M, Sandalova E, Low D, et al. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun. 2015;6:6588.
   PubMed Web of Science ®Google Scholar
• Locarnini S, Hatzakis A, Chen D, et al. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62(1):S76–86.
   PubMed Web of Science ®Google Scholar